Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYPO-AVOID: Low-dose glucagon with advanced hybrid closed-loop system to prevent exercise-induced hypoglycaemia in type 1 diabetes
2021-004993-68Phase 2Completed
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of glucagon in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Steno Diabetes Center Copenhagen. Started Oct 2021; status: completed.
02
Drugs
glucagon
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2021-004993-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004993-68.